Real-world Patient Reported Outcomes Among Patients Treated With Camzyos

Inclusion Criteria:

• Participants ≥18 years of age.

• Participants who are prescribed mavacamten for obstructive hypertrophiccardiomyopathy

• Provided informed consent to participate in the study

Exclusion Criteria:

• Previously or currently enrolled in clinical trials for any cardiac myosininhibitors

• Treated for >7 days with mavacamten by the day of completing the baseline survey

• Enrolled in any clinical trials at the time of or within the six-month period priorto the screening

• Had heart attack requiring coronary artery bypass grafting within the three-monthperiod prior to the screening

• Had stroke or transient ischemic attack within the six-month period prior to thescreening

• Had moderate-to-severe lung disease which impacted the ability to perform dailyactivities of living and ability to breathe

• Had major lung (thoracic) or heart (cardiac) surgery within the six-month periodprior to the screening

• Scheduled for a major surgery for the next three months, such as joint surgeriesincluding hip replacement, abdominal surgeries, lung surgeries, heart surgeries, eyesurgeries, brain surgeries, and any other major surgeries that require generalanesthesia and at least an overnight hospital stay

• Hospitalized requiring an overnight stay at the time of or within the two-weekperiod prior to the screening